Research Article
Exploring the Role of Breast Density on Cancer Prognosis among Women Attending Population-Based Screening Programmes
Table 2
Tumour characteristics by breast density categories.
| | | Total n = 375 (%) | Low breast density (<25%) n = 192 (%) | Intermediate breast density (25–50%) n = 104 (%) | High breast density (>50%) n = 79 (%) |
| | Mode of detection | | Screen-detected cancers | 195 (52) | 113 (58.9) | 45 (43.3) | 37 (46.8) | | Interval cancer | 180 (48) | 79 (41.1) | 59 (56.7) | 42 (53.2) | | Tumour size | | <20 mm | 199 (61.8) | 108 (56.3) | 53 (51) | 38 (48.1) | | ≥20 mm | 123 (38.2) | 58 (30.2) | 33 (31.7) | 32 (40.5) | | Lymph node involvement | | Negative | 218 (66.1) | 117 (60.9) | 60 (57.7) | 41 (51.9) | | Positive | 112 (33.9) | 51 (26.6) | 30 (28.8) | 31 (39.2) | | Focality | | Unifocal | 301 (84.6) | 155 (87.1) | 80 (80) | 66 (84.6) | | Multifocal and/or multicentric | 55 (15.4) | 23 (12.9) | 20 (20) | 12 (15.4) | | Histological type | | Ductal | 303 (80.8) | 152 (79.2) | 86 (82.7) | 65 (82.3) | | Lobular | 39 (10.4) | 22 (11.5) | 8 (7.7) | 9 (11.4) | | Others | 33 (8.8) | 18 (9.4) | 10 (9.6) | 5 (6.3) | | Histological grade | | I | 83 (23.9) | 44 (22.9) | 18 (17.3) | 21 (26.6) | | II | 134 (38.5) | 64 (33.3) | 40 (38.5) | 30 (38) | | III | 116 (33.3) | 60 (31.3) | 35 (33.7) | 21 (26.6) | | NA | 15 (4.3) | 9 (4.7) | 3 (2.9) | 3 (3.8) | | Oestrogen receptor | | Negative | 88 (23.5) | 46 (24) | 28 (26.9) | 14 (17.7) | | Positive | 287 (76.5) | 146 (76) | 76 (73.1) | 65 (82.3) | | Progesterone receptor | | Negative | 150 (40.1) | 70 (36.5) | 45 (43.3) | 35 (44.3) | | Positive | 224 (59.9) | 121 (63) | 59 (56.7) | 44 (55.7) | | HER2 | | Negative | 261 (79.1) | 133 (69.3) | 70 (67.3) | 58 (73.4) | | Positive | 69 (20.9) | 35 (18.2) | 21 (20.2) | 13 (16.5) | | Ki67 | | Negative | 114 (60.3) | 62 (32.3) | 29 (27.9) | 23 (29.1) | | Positive | 75 (39.7) | 49 (25.5) | 15 (14.4) | 11 (13.9) | | Tumour phenotype | | Luminal A | 155 (48) | 79 (41.1) | 38 (36.5) | 38 (48.1) | | Luminal B | 93 (28.8) | 46 (24) | 26 (25) | 21 (26.6) | | HER2 | 31 (9.6) | 11 (5.7) | 12 (11.5) | 8 (10.1) | | Triple-negative | 44 (13.6) | 29 (15.1) | 11 (10.6) | 4 (5.1) | | Treatment | | Conservative surgery only or with sentinel lymph node biopsy | 97 (26.4) | 50 (26.4) | 28 (28) | 19 (24.1) | | Conservative surgery with axillary lymph node dissection | 182 (49.5) | 100 (52.9) | 44 (44) | 38 (48.1) | | Radical surgery with or without lymphadenectomy | 79 (21.5) | 35 (18.5) | 24 (24) | 20 (25.3) | | No surgery and/or adjuvant treatment | 10 (2.7) | 4 (2.1) | 4 (4) | 2 (2.5) | | Adjuvant treatment after surgery | | Chemotherapy, radiotherapy, and hormonal therapy | 122 (32.5) | 54 (28.1) | 36 (34.6) | 32 (40.5) | | Radiotherapy and hormonal therapy | 123 (32.8) | 68 (35.4) | 35 (33.7) | 20 (25.3) | | Other treatments | 130 (34.7) | 70 (36.5) | 33 (31.7) | 27 (34.2) |
|
|
